Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NVCR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNovoCure equity plan narrowly passes with 50.3% support amid shareholder division
Filed June 5, 2026 · Period ending June 3, 2026 · ~1 min read
Key Changes
-
high
Amended equity incentive plan approved by razor-thin margin: 41.7M shares for vs. 41.2M against (50.3% support). Near-even split signals significant shareholder concern over dilution from stock-based compensation.
Item 5.07 verify on EDGAR → -
medium
Say-on-pay approved with 91% support (75.4M for, 7.4M against). Opposition of 9% is within normal range for executive compensation votes.
Item 5.07 verify on EDGAR → -
medium
All 11 directors elected with 95.7%–99.6% support. Kinyip Gabriel Leung received lowest support at 95.9% (79.5M for vs. 3.4M against); Frank Leonard highest at 99.6%.
Item 5.07 verify on EDGAR → -
low
Auditor Kost Forer Gabbay & Kasierer (EY Global member) ratified with 97.5% support (91.4M for, 2.3M against).
Item 5.07 verify on EDGAR → -
low
Annual meeting achieved 81% turnout (93.8M shares represented of 115.8M entitled to vote), indicating strong shareholder participation.
Item 5.07 verify on EDGAR →
Summary
NovoCure's June 3, 2026 annual meeting produced a contentious outcome on equity compensation. The company's Amended and Restated 2024 Omnibus Incentive Plan squeaked through with just 50.3% support—41.7 million shares voted for versus 41.2 million against.
This near-even split reveals deep shareholder division over stock-based compensation dilution, a concern that has grown across the biotech sector as investors scrutinize equity burn rates. The narrow approval means management secured the plan but faces a clear mandate to address dilution concerns before the next equity ask. Other voting results were routine.
Say-on-pay passed with 91% support, well within healthy ranges. All eleven directors won election with 96%–100% support, and the auditor ratification sailed through at 97.5%. The 81% shareholder turnout reflects solid engagement. The equity plan vote stands out as the sole area of material contention—watch whether NovoCure adjusts its equity compensation strategy or faces renewed opposition at the 2027 meeting.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
NovoCure held its 2026 annual meeting and elected 11 directors to serve until the 2027 annual meeting.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The Company’s shareholders elected Asaf Danziger, William Doyle, Jeryl Hilleman, David Hung, Frank Leonard, Kinyip Gabriel Leung, Martin Madden, Allyson Ocean, Timothy Scannell, Kristin Stafford and William Vernon as directors, effective immediately, with a term expiring at the annual meeting of shareholders in 2027.
At the June 3, 2026 annual meeting, shareholders elected eleven directors to the board with terms running until the 2027 annual meeting. The filing does not disclose vote tallies or turnout, so the level of shareholder support cannot be determined. All directors will receive standard non-employee director compensation.
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
NovoCure held its 2026 annual meeting with 81% turnout; all directors elected, auditor ratified, say-on-pay approved, equity plan narrowly passed.
Added in current filing · verify on EDGAR →
Asaf Danziger 81,489,6091,388,51274,47910,874,130 William Doyle 80,241,0092,664,19047,40110,874,130 Jeryl Hilleman 81,547,8201,293,373111,40710,874,130 David Hung 80,768,3252,039,529144,74610,874,130 Frank Leonard 82,547,254356,49448,85210,874,130 Kinyip Gabriel Leung 79,455,7543,370,420126,42610,874,130 Martin Madden 81,360,6411,461,539130,42010,874,130 Allyson Ocean 81,178,2951,666,945107,36010,874,130 Timothy Scannell 81,540,5311,292,301119,76810,874,130 Kristin Stafford 81,584,3981,272,04596,15710,874,130 William Vernon 81,349,4101,483,356119,83410,874,130
All eleven director nominees were elected to serve until the 2027 annual meeting. Support ranged from 95.7% to 99.6% of votes cast (For votes divided by For+Against+Abstain). The lowest support went to Kinyip Gabriel Leung with 79,455,754 For votes versus 3,370,420 Against, while Frank Leonard received the highest support with 82,547,254 For votes versus 356,494 Against.
Added in current filing · view on EDGAR →
ForAgainstAbstainBroker non-votes 75,392,1687,422,876137,55610,874,130
The non-binding advisory vote on executive compensation passed with 91.0% support of votes cast (75,392,168 For out of 82,952,600 votes cast excluding broker non-votes). This represents 80.4% support relative to the 93,826,730 total shares represented at the meeting. The 8.96% opposition (7,422,876 Against votes) is within normal ranges for say-on-pay votes.
Added in current filing · view on EDGAR →
ForAgainstAbstainBroker non-votes 41,680,62241,161,139110,83910,874,130
The Amended and Restated 2024 Omnibus Incentive Plan narrowly passed with 50.3% support of votes cast (41,680,622 For out of 82,952,600 votes cast excluding broker non-votes). The near-even split—41,680,622 For versus 41,161,139 Against—indicates significant shareholder division on equity compensation dilution. This represents only 44.4% support relative to total shares represented at the meeting.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 21, 2026 · How we verify